<DOC>
	<DOCNO>NCT02562599</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety raltitrexed cisplatin neoadjuvant chemotherapy follow concurrent radiotherapy raltitrexed cisplatin patient locally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Chemoradiotherapy Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin</brief_title>
	<detailed_description>Although concurrent chemoradiation standard treatment modality locally advanced nasopharyngeal carcinoma ( NPC ) , high incidence distant metastasis severe treatment related toxicity become obstacle overcome . A phase â…¡ study conduct Hui et al . show neoadjuvant chemotherapy follow concurrent chemoradiotherapy superior standard concomitant chemoradiation term 3-year OS without significantly exacerbate acute toxicity . At present , PF regimen consider classic chemotherapy regimen nasopharyngeal carcinoma ( NPC ) , efficiency 40 % -60 % , always severe gastrointestinal reaction , renal toxicity oral mucosa reaction . Therefore , imperative find safe effective chemotherapy regimen . Raltitrexed specific thymidylate synthase inhibitor convenient administration schedule , acceptable manageable toxicity , radiosensitising property . It may offer advantage compare standard 5-FU chemotherapy regimen use locally advanced NPC . Therefore , investigator initiate study evaluate efficacy safety raltitrexed cisplatin neoadjuvant chemotherapy follow concurrent radiotherapy raltitrexed cisplatin patient locally advanced NPC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients newly histologically confirm nasopharyngeal carcinoma , include WHO III 2 . Newly diagnose T34 TN23 locally advance nasopharyngeal carcinoma 3 . At least one measurable lesion ( accord RECIST1.1 ) 4. female male,1870 year age 5 . ECOG performance status 01 6 . Life expectancy 3 month 7 . Without radiotherapy chemotherapy 8 . Adequate organ function include follow : Platelets count &gt; = 100 * 109/l Absolute neutrophil count ( ANC ) &gt; = 2.0 * 109/l Hemoglobin &gt; = 90 g/l Total bilirubin &lt; = 1.5ULN AST ALT &lt; = 2.5ULN , liver metastasis , AST ALT &lt; = 5ULN Serum creatine &lt; = 1.5ULN 9 . Signed date informed consent . 1 . Before time second malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix 2 . Evidence distant metastasis 3 . Taboos chemotherapy radiotherapy ( heart failure , angina pectoris , cardiac arrhythmia.et al ) Presence uncontrolled concomitant illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia 4 . Pregnant breastfeeding female 5 . Abuse psychiatric drug dysphrenia 6 . Prior chemotherapy raltitrexed cisplatin 7 . Allergic clinical drug 8 . Participation clinical trial antitumor drug 4 week 9 . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Concurrent Chemoradiotherapy</keyword>
</DOC>